Response to Chiasson et al.: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data

Sawicki, Peter T.; Kaiser, Thomas

doi:10.1007/s00125-004-1410-y

Cited by 14 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acarbose was reported to reduce cardiovascular events in a secondary analysis of the STOP-NIDDM trial, 7 but with only 47 participants having the outcome in question this could be a chance finding. 19 The lack of any substantial benefit on cardiovascular events in ACE compared with STOP- 21 Nateglinide, a rapid-acting insulin secretagogue which reduces postprandial hyperglycemia by increasing circulating insulin levels, was evaluated in the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. In patients at high cardiovascular disease risk and with impaired glucose tolerance followed for median 5•0 years, nateglinide 120 mg once daily showed no effect on the risk of cardiovascular events and a 7% significant increased risk for new-onset diabetes.…”

Section: Discussionmentioning

confidence: 99%

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

Holman¹,

Coleman²,

Chan³

et al. 2017

The Lancet Diabetes & Endocrinology

275

180

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

Holman¹,

Coleman²,

Chan³

et al. 2017

The Lancet Diabetes & Endocrinology

275

180

View full text Add to dashboard Cite

show abstract

“…After a mean follow-up of 3.3 years, the acarbose-treated group achieved 25 % and 36% RR reduction based on one or two OGTTs in progression to diabetes compared with placebo. The effect of acarbose was observed across all ages, at all BMIs, and in both sexes, while there was some evidence of an accompanying improvement in CVD risks [255][256][257].…”

Section: Antiobesity Treatmentmentioning

confidence: 87%

A European Evidence-Based Guideline for the Prevention of Type 2 Diabetes

Paulweber¹,

Valensi²,

Lindström³

et al. 2010

Horm Metab Res

430

332

View full text Add to dashboard Cite

!Background: The prevalence and socioeconomic burden of type 2 diabetes (T2DM) and associated co-morbidities are rising worldwide. Aims: This guideline provides evidence-based recommendations for preventing T2DM. Methods: A European multidisciplinary consortium systematically reviewed the evidence on the effectiveness of screening and interventions for T2DM prevention using SIGN criteria. Results: Obesity and sedentary lifestyle are the main modifiable risk factors. Age and ethnicity are non-modifiable risk factors. Case-finding should follow a step-wise procedure using risk questionnaires and oral glucose tolerance testing. Persons with impaired glucose tolerance and/or fasting glucose are at high-risk and should be prioritized for intensive intervention. Interventions supporting lifestyle changes delay the onset of T2DM in high-risk adults (numberneeded-to-treat: 6.4 over 1.8-4.6 years). These should be supported by inter-sectoral strategies that create health promoting environments. Sustained body weight reduction by ≥ 5% lowers risk. Currently metformin, acarbose and orlistat can be considered as second-line prevention options. The population approach should use organized measures to raise awareness and change lifestyle with specific approaches for adolescents, minorities and disadvantaged people. Interventions promoting lifestyle changes are more effective if they target both diet and physical activity, mobilize social support, involve the planned use of established behaviour change techniques, and provide frequent contacts. Cost-effectiveness analysis should take a societal perspective. Conclusions: Prevention using lifestyle modifications in highrisk individuals is cost-effective and should be embedded in evaluated models of care. Effective prevention plans are predicated upon sustained government initiatives comprising advocacy, community support, fiscal and legislative changes, private sector engagement and continuous media communication.

show abstract

“…9 However, the small number of cardiovascular events in that study, challenges the validity of the observations, and criticisms of the study execution, end point definition and data reporting have been debated. [10][11][12] No long-term data from the DPP are presently available. Moreover, the risk of developing DM after discontinuing either medical regimen remains unknown.…”

Section: Introductionmentioning

confidence: 99%

Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus

McGuire

Winterfield

Rytlewski

et al. 2008

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

Type 2 diabetes mellitus (DM) is increasing around the world, and the public health impact of DM, driven largely by cardiovascular disease complications, underpins the importance of continued efforts toward primary prevention of DM. Only a few interventions have been shown to prevent DM, with none of them yet proven to improve cardiovascular risk commensurately. Accumulating evidence suggest that drugs that block the renin-angiotensin-aldosterone system (RAAS), many of which have proven cardiovascular disease (CVD) benefit, also have favourable effects on parameters of glucose metabolism and incident diabetes. Here we review the evidence accumulated to date from animal studies, clinical mechanistic studies and clinical trials regarding the effect of RAAS inhibition and incident DM.

show abstract

Response to Chiasson et al.: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data

Cited by 14 publications

References 9 publications

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

A European Evidence-Based Guideline for the Prevention of Type 2 Diabetes

Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus

Contact Info

Product

Resources

About